Validation of the MD Anderson Symptom Stock-Head-and-Neck-Filipino (MDASI-HN-F): medical utility of symptom screening amongst sufferers with head-and-neck most cancers.
BMJ Help Palliat Care. 2017 Jun;7(2):140-149
Authors: Bacorro WR, Sy Ortin TT, Suarez CG, Mendoza TR, Que JC
CONTEXT: Symptom burden and high quality of life (QOL) are of explicit significance in head-and-neck most cancers therapy. The MD Anderson Symptom Stock-Head-and-Neck (MDASI-HN) is an easy symptom evaluation software practicable for affected person follow-up, however a validated Filipino translation was beforehand unavailable.
OBJECTIVES: The goals of this research have been to develop a sound Filipino translation of the MDASI-HN, to check the sensitivity of the validated MDASI core-F, and to report the prevalence and sample of head-and-neck signs in our cohort.
METHODS: An MDASI-HN-Filipino (MDASI-HN-F) model was developed and examined for convergent validity, inside consistency, test-retest reliability, known-group validity and sensitivity to alter. Eligible members have been aged 18-80?years, with histopathologically-proven head-and-neck (besides thyroid) most cancers, in a position to perceive and browse English and Filipino, and with out cognitive impairment or different circumstances precluding self-administration of the questionnaire.
RESULTS: Members (n=100) have been aged 18-76?years; the bulk have been aged <60, male, married, had school education, or have been from a Tagalog-speaking area. The validity of the MDASI HN-F was demonstrated in all parameters. Age or academic attainment didn’t have an effect on convergent validity or test-retest reliability. At baseline, 48% had a number of reasonable/extreme signs and 38% had at the least one extreme symptom.
CONCLUSIONS: The MDASI-HN-F is legitimate, dependable and delicate. The sensitivity of the MDASI core-F is demonstrated, and its validity and reliability reaffirmed. Average and extreme head-and-neck signs are prevalent in early-stage and advanced-stage head-and-neck cancers, reflecting the utility of symptom screening for enchancment of symptom administration, QOL and compliance to therapy.
PMID: 25941198 [PubMed – indexed for MEDLINE]